In the book, Attia distinguishes between standard medical thinking, what he calls Medicine 2.0, and his approach, Medicine 3.0
Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs
Do not use TALTZ if it has been frozen
Cada cpsula contiene pptido farmacuticamente puro, sintetizado en Europa y probado en laboratorios acreditados en Polonia, Alemania y Suiza
demonstrated that exposure to GLP-1 for 30 min did not induce changes to glycolytic and TCA cycle intermediates in MIN6-K8 cells 40
By keeping the medication within the recommended temperature range, you are protecting the integrity of the treatment and ensuring you stay on track with your health goals